-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 16, AstraZeneca announced that Klygefa, a drug developed by Alexion, has been approved by the European Union and the United States to treat adult systemic myasthenia gravis patients with positive anti-acetylcholine receptor antibodies. This drug is a dual-targeted nanoantibody C5 inhibitor that can be injected subcutaneously once a week via an autoinjector. This approval is based on the results of the Phase III PREVAIL trial. The trial showed that the drug significantly improved the patient's ability to perform daily living activities in the 26th week, and clinical improvements first appeared in the first week of medication. The drug became the first dual-target nanoantibody C5 inhibitor approved in both the EU and the US.
Share
Listen to the news
On November 16, AstraZeneca announced that Klygefa, a drug developed by Alexion, has been approved by the European Union and the United States to treat adult systemic myasthenia gravis patients with positive anti-acetylcholine receptor antibodies. This drug is a dual-targeted nanoantibody C5 inhibitor that can be injected subcutaneously once a week via an autoinjector. This approval is based on the results of the Phase III PREVAIL trial. The trial showed that the drug significantly improved the patient's ability to perform daily living activities in the 26th week, and clinical improvements first appeared in the first week of medication. The drug became the first dual-target nanoantibody C5 inhibitor approved in both the EU and the US.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending